The aim of this study was to analyze whether procalcitonin (PCT) is a diagnostic marker of infectious diseases during the non-neutropenic period in patients who have received an allogeneic hematopoietic stem cell transplant (HSCT). We included 65 patients in whom an allogeneic HSCT was performed in a 2-year period (April 2002-July 2004. PCT levels were monitored in every febrile episode by an immunoluminometric assay. Febrile episodes were classified according to the final diagnosis in: fever of unknown origin, microbiologically or clinically documented infection and non-infectious fever. Fifty-two febrile episodes in the non-neutropenic period were included in the study. Out of these 52, 26 had an infectious etiology: 11 fulfilled criteria for probable or proven invasive aspergillosis (IA), three were classified as possible invasive fungal infection (IFI) and 12 episodes were caused by other infections. Mean values of PCT on the first day of admission were: 8.0 (74.9) in probable-proven IA (P ¼ 0.013, Kruskall-Wallis), 4.5 (73.4) in possible IFI and 1.5 (70.9) in infections other than IFI. Therefore, we could conclude that during the non-neutropenic phases of allogeneic HSCT, a high PCT value is associated significantly with IA.
Introduction
Procalcitonin (PCT) has been proposed as a discriminative marker of infectious diseases in immunocompetent patients because infection is associated with high PCT levels exceeding 1.5 ng/ml. [1] [2] [3] In neutropenic patients, PCT usefulness in the differential diagnosis of febrile episodes has been analyzed in several studies. Fleischhack et al. 4 have evaluated PCT, C-reactive protein (CRP) and endotoxin plasmatic values in 122 febrile episodes of neutropenic children. According to their results, PCT (optimum cutoff level 0.5 ng/l) was more sensitive and specific for diagnosis of high-risk (gramnegative bacteremia) and low-risk (fever of unknown origin) episodes than the remaining inflammatory makers evaluated. However, Svaldi et al. 5 observed that PCT was a sensitive marker of sepsis with a high positive-and negative predictive value for patients when leukocytes are above 1000/ml, but not when they were below this count.
Few studies have been performed in hematopoietic stem cell transplantation (HSCT) recipients. Blijlevens et al. 6 observed that PCT was of little value in discriminating infections from other inflammatory complications that occurred following allogeneic HSCT. Recently, Sauer et al. 7 published a prospective evaluation of capability of serum PCT compared with CRP to identify children with a high risk of mortality from sepsis after HSCT. They concluded that median concentrations of PCT, in contrast to serum CRP and endotoxin, correlated with the severity of sepsis and provided useful prognostic information during septic episodes.
In our institution, since April 2002, we have prospectively tested CRP 8 and PCT 9 during neutropenic febrile episodes following HSCT. According to our previous results, PCT on the first day of a febrile neutropenic episode in adults after HSCT was not useful in the differential diagnosis. However, in cases of fever persisting after 5 days of empiric antibiotic therapy, a PCT X3 ng/ml was a sensitive and specific marker of invasive aspergillosis (IA).
The aim of this study was to analyze if PCT is an early diagnostic marker of infectious diseases during the nonneutropenic period after allogeneic HSCT in adult patients.
Patients and methods
Between April 2002 and July 2004, all consecutive patients who were admitted to receive an allogeneic HSCT in our institution were included in the study. As explained in our previous study, 9 all patients received as anti-infection prophylaxis, ciprofloxacin 500 mg twice a day p.o. from their admission until neutrophil recovery, and fluconazole daily until day þ 60 post-HSCT (400 mg/day in unrelated donor HSCT and 50 mg in remaining cases). On admission and every 28 days until discharge, patients received inhaled pentamidine as Pneumocystis jirovecii infection prophylaxis and when neutrophils were 1.0 Â 10 9 /l, they were changed to cotrimoxazole. Patients who were seropositive for herpes virus simplex (HVS) received 800 mg of oral aciclovir every 12 h until day þ 28 post HSCT. Pre-emptive therapy was used for cytomegalovirus (CMV) infection control, and Aspergillus galactomannan antigenemia (AGA) was analyzed prospectively twice a week. During the procedure, patients remained hospitalized in an isolation unit with laminar airflow protection while neutropenic. After discharge, all patients were followed in the outpatient clinic weekly during the first 3 months, and, thereafter, every 15 days during the next 6 months, with clinical, analytical and microbiological tests (CMV antigenemia and AGA as often as needed until the end of immunosuppression).
When the patient was in the non-neutropenic phase (absolute neutrophil count, ANC, above 0.5 Â 10 9 /l) and had fever (axillar temperature X381C), clinical, analytical, microbiological and radiological investigations were performed and empirical antimicrobial treatment was started according to the protocols of our institution. PCT was determined every 48 h from the day the patient came to the hospital until the day of resolution of fever. Serum concentrations of PCT were determined by an immunoluminometric assay (DiaSorin, Saluggia, Italy). The detection limit was 0.04 ng/ml.
Febrile episodes were classified in four major groups (the values of PCT were not included in the classification criteria): (1) Documented microbiological infection: bacterial infection if a pathogenic microorganism was isolated from a sterile sample or an opportunist microorganism (coagulase-negative Staphylococcus or Corynebacterium spp.) isolated from two consecutive blood cultures; fungal or viral infection, when a fungus was isolated from a sterile sample or serological tests were positive, antigens or DNA were detected. For diagnosis of invasive fungal infection (IFI), the criteria proposed by Ascioglu et al. 10 according to the EORTC/MSG criteria were used, and for diagnosis of CMV infection the criteria proposed by Ljungman et al.
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(2) Clinically documented infection, febrile episodes with a clinical focus of infection and negative cultures. (3) Noninfectious febrile episode, when a non-infectious etiology was identified as the cause of fever. (4) Fever of unidentified cause, an episode that could not be classified in any of the previous groups.
The ELISA test (Platelia Aspergillus; Sanofi Diagnostics Pasteur, Marnes-La Coquette, France) was used for AGA monitoring and interpreted according to the manufacturer's recommendations as previously explained. 12 Results were expressed as the ratio (index) between the optical densities (ODs) obtained from the patient's serum sample and the control (index ¼ OD of the sample/OD of the control). An index greater than 1.5 was considered positive. Results between 1.0 and 1.5 (gray zone) were considered undetermined. An index below 1.0 was negative. When a serum sample was undetermined, an additional sample was immediately tested. Statistical analyses were carried out by the program SPSS (version 9.0; SPSS, Inc., Chicago, IL, USA). Continuous variables were expressed as mean and standard deviation (7s.d.) or median (range) according to their homogeneity. Categorical variables were compared using the w 2 test or the Fisher exact test (when necessary). Quantitative variables were compared by the StudentFisher t test or ANOVA. Non-parametric tests were used elsewhere. Statistical significance was defined as a twotailed P-value o0.05.
All Table 1 shows the main clinical characteristics, hematological diseases and procedures of the 50 patients included in the study.
The final diagnoses of febrile non-neutropenic episodes are shown in Table 2 . There were 26 microbiologically or clinically documented infections, 19 febrile episodes of unknown origin and seven non-infectious fevers. Out of 26 cases with an infectious etiology, 21 were confirmed microbiologically and five clinically. The most frequently documented infections were proven or probable IA and they accounted for 11 cases (two cases of Aspergillus spp. isolated from bronchoalveolar lavage, nine cases of probable IA with a minimum of two positive consecutive AGA), and three possible IFI.
In Table 3 ,we analyze the PCT on first day of admission in non-neutropenic phase according to fever etiology. Mean (7s.d.) PCT values on the first day of admission in these cases were: 8.0 (74.9) in 11 probable-proven IA, 4.5 (73.4) in three possible IFI and 1.5 (70.9) in 12 cases of other infection (P ¼ 0.013, Kruskal-Wallis).
A value X3 ng/ml of PCT on the first day of admission was associated with IA in non-neutropenic febrile episodes of allogeneic HSCT recipients with a sensitivity of 100%, a specificity of 95% and predictive positive and negative values of 84 and 100%, respectively.
Discussion
According to our results, PCT is a useful tool for clarifying the diagnosis in episodes of non-neutropenic fever after allogeneic HSCT because on first day of admission, a PCT X3 ng/ml identified patients with IA with a high sensitivity and specificity. In our previous study, 9 PCT on the first day of a febrile neutropenic episode in adults after HSCT was not useful in the differential diagnosis, but in cases of persistent fever after 5 days of empiric therapy, a PCT X3 ng/ml was a sensitive and specific marker of IA.
Diagnosis of IA in hematology patients remains difficult, although in recent years new diagnostic tests have been developed. 12, 13 As is known, these tests do not replace other diagnostic tools in the work-up of unexplained fever in patients at risk and if they are used, it is mandatory to prospectively monitor twice weekly. In this context, PCT could have a role in the investigation of febrile episodes after allogeneic HSCT, especially in centers with nonstandarization of microbiological tests.
In our previous study, 9 in IA cases, the PCT value was normal in the first 24 h of fever during neutropenia but increased after 5 days of fever and antibiotic empiric therapy. In the present study, PCT was a marker of IA infection on the first day of admission in patients with nonneutropenic fever. This difference could be explained to a delay in PCT determination in the second study, as the patient begins with fever at home and afterwards (some hours or 1 or 2 days) is admitted at hospital. When the patient is in the neutropenic phase, fever appears during the admission, and the first PCT determination is always taken in the first 24 h of fever. In the first study, we took the second PCT determination on the fifth day of fever. Therefore, we do not know which is the PCT profile between the first and the fifth day of neutropenic fever in IA cases (the PCT may begin to rise on the second or the third day of infection evolution). However, along the non-neutropenic phase, the first determination of PCT is variable, with a median delay of 3 days. Therefore, the fifth day of fever in the neutropenic phase could correspond to the first day of admission in the non-neutropenic phase, given that in both cases the response of PCT and the levels reached were similar (discriminative PCT value of 3 ng/ml in IA infection).
However, the explanation could be that, despite its potential clinical usefulness, little is known about the biological properties of PCT and its source of origin. Linscheid et al. 14 claimed in their study that infectious and inflammatory causes can lead to an initial priming of monocytes with transient PCT expression and secretion, followed by monocyte recruitment at the site of infection. This transient PCT secretion is primarily limited locally and may explain the only moderately elevated serum levels in localized infections. 15 The major source of PCT in severe sepsis and septic shock seems to originate from parenchymal cells (i.e. adipocytes). According to this physiopathological explanation, it is probable that the response of PCT to IFI in the neutropenic phase has a delay and it is detectable only after several days of infection.
Future investigations in experimental models should determine if this delay also applies in the neutropenic phase and also if this biochemical behavior is similar in different fungal mould infections. In IFI, it would be very interesting to understand the mechanisms of release of PCT and to know the role of mononuclear and parenchymal cells.
In conclusion, PCT determination is useful also in HSCT patients with non-neutropenic fever. PCT elevation in patients with fever after an allogeneic HSCT without neutropenia identifies patients with IA with high sensitivity and specificity at the moment of admission. In this population, all diagnostic and therapeutic efforts should be commenced promptly to improve outcome.
